131288-67-0

Basic information

• Product Name: (S)-2-AMINO-3-CYCLOHEXYL-PROPAN-1-OL
• Synonyms: H-CHA-OL;L-CYCLOHEXYLALANINOL;H-PHE(HEXAHYDRO)-OL;(S)-2-AMINO-3-CYCLOHEXYL-PROPAN-1-OL;(S)-CYCLOHEXYLALANINOL;()-cyclohexylalaninol;(S)-2-amino-3-cyclohexyl-1-propanol;(2S)-2-amino-3-cyclohexyl-1-propanol(SALTDATA: HCl)
• CAS NO: 131288-67-0
• Molecular Formula: C₉H₁₉NO
• Molecular Weight: 157.25
• Product Categories: Amino Alcohols;pharmacetical
• Mol File: 131288-67-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 289.5 °C at 760 mmHg
• Flash Point: 128.9 °C
• Appearance: /
• Density: 0.97 g/cm³
• Storage Temp.: 2-8°C(protect from light)
• PKA: 12.86±0.10(Predicted)
• CAS DataBase Reference: (S)-2-AMINO-3-CYCLOHEXYL-PROPAN-1-OL(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-AMINO-3-CYCLOHEXYL-PROPAN-1-OL(131288-67-0)
• EPA Substance Registry System: (S)-2-AMINO-3-CYCLOHEXYL-PROPAN-1-OL(131288-67-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• Hazardous Substances Data: 131288-67-0(Hazardous Substances Data)

Usage

General Description

"(S)-2-AMINO-3-CYCLOHEXYL-PROPAN-1-OL" is a chemical compound that belongs to the class of organic chemicals known as cyclohexylamines. These compounds contain an amine group connected to a cyclohexane ring. In this specific compound, the cyclohexyl group is attached to the Beta Carbon of a propanol group. The '(S)-' prefix in the name denotes the specific optical isomer of the molecule that is present, which is important because isomers can have different properties and biological activities. This chemical is often used in research settings, particularly in synthetic chemistry. Its features and properties such as molecular weight, boiling point, melting point, and specific optical rotation can be calculated specifically. Its interactions, toxic level, biological activity and medicinal use are mainly determined through experimental research.

Upstream product

• 103322-56-1 tert-butyl [(1S)-2-cyclohexyl-1-(hydroxymethyl)ethyl]carbamate 
• 27527-05-5 L-cyclohexylalanine 
• 3182-95-4 L-Phenylalaninol 
• 2577-90-4 methyl (2S)-2-amino-3-phenylpropanoate 
• 66605-57-0 (S)-N-tert-butoxycarbonyl-2-amino-3-phenylpropanol 

Downstream Products

• 103322-56-1 tert-butyl [(1S)-2-cyclohexyl-1-(hydroxymethyl)ethyl]carbamate 
• 129593-15-3 (-)-N-((S)-1-hydroxy-3-cyclohexylpropyl)benzamide 
• 130317-11-2 (S)-5-Cyclohexylmethyl-2-oxo-morpholine-4-carboxylic acid tert-butyl ester 
• 253449-29-5 ethyl N-<4-(2(S)-3-cyclohexyl-1-hydroxypropan-2-ylaminomethyl)-2-(2-methylphenyl)benzoyl>-L-methionine 
• 142758-96-1 (4S)-4-(cyclohexylmethyl)-2-oxazolidinone 
• 926647-49-6 (4S)-2-[3-(2-bromophenyl)-1-phenylpropyl]-4-cyclohexylmethyl-2-oxazoline 

Relevant articles and documents

Highly enriched mixtures of methohexital stereoisomers by palladium-catalyzed allylation and their anaesthetic activity

The stereoselective Pd-catalyzed allylation of MBA [5-(2′-hex-3′-yny1)-1-methylbarbituric acid] gives the commercial injection narcotic methohexital, which exists as four isomers: two diastereomeric pairs of enantiomers. The isomer composition produced depends on three stereochemical parameters: catalyst control, substrate control, and kinetic resolution. Judicious choice of these parameters allowed the synthesis of methohexital samples with greatly differing isomer compositions, and these samples were investigated with respect to their anaesthetic doses in rats. Some isomer compositions obtained were much more active than the commercially used drug and showed fewer side effects. As a consequence of the determination of the absolute configuration of the methohexital (SbRh) isomer, the unknown configuration of the trade product, the so-called α-racemate, can be established as (RbSh) and (SbRh). ( Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003).

CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT

Disclosed are novel compounds of the formula (I)or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is formula (I) X is -0-, -C(R14)2- or -N(R)-; Z is -C(R14)2- or -N(R)-; t is 0, 1, 2 or 3; each R and R2 is independently H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, alkenyl or alkynyl; each R14 is H, alkyl, alkenyl, alkynyl, halo, -CN, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, -OR35, -N(R24)(R25)or -SR35; R41 is alkyl, cycloalkyl, -S02(alkyl), -C(O)-alkyl, -C(O)-cycloalkyl or -alkyl-NH-C(O)CH3; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating cognitive or neurodegenerative diseases with compounds of formula (I). Also disclosed are pharmaceutical compositions and methods of treatment comprising compounds of formula I in combination with other agents useful in treating cognitive or neurodegenerative diseases.

Large scale synthesis of optically pure aziridines

Disclosed is an efficient, inexpensive method for the preparation of chiral aziridines on a large scale.